CytomX Therapeutics shares are trading higher after the company announced Phase 1 expansion data for its EpCAM PROBODY antibody-drug conjugate, varsetatug masetecan, in late-line metastatic colorectal cancer.

Benzinga Newsdesk www.benzinga.com Positive 95.4%

Neg 0% Neu 0% Pos 95.4%

Comments

No comments yet. Be the first!